Evaluation of enhanced external counterpulsation therapy for nonarteritic anterior ischemic optic neuropathy

BMC Ophthalmology

Table 2 Visual function differences among groups at baseline and 2- and 6-month follow-up

	Total	Control group	EECP group			P value ^a	P value ^b
				EECP initiated within 2 weeks	EECP initiated after 2 weeks	(t-test)	(ANOVA)
Eyes (n)	76	39	37	8	29
BCVA
Baseline	0.87 ± 0.93	0.99 ± 1.14	0.74 ± 0.62	0.66 ± 0.48	0.76 ± 0.65	0.095	0.492
Month 2	0.79 ± 0.72	0.82 ± 0.68	0.76 ± 0.76	0.80 ± 0.52	0.75 ± 0.83	0.954	0.926
Change (2–0)	−0.07 ± 0.52	−0.16 ± 0.59	0.02 ± 0.44	0.15 ± 0.25	−0.01 ± 0.47	0.261	0.211
Month 6	0.75 ± 0.61	0.72 ± 0.51	0.77 ± 0.72	0.83 ± 0.92	0.67 ± 0.62	0.174	0.145
Change (6–0)	0.01 ± 0.43	− 0.02 ± 0.35	0.04 ± 0.51	0.21 ± 0.32	− 0.05 ± 0.41	0.264	0.054
MD
Baseline	−20.09 ± 9.27	−19.26 ± 9.81	−20.93 ± 8.77	−18.97 ± 7.07	−21.48 ± 9.24	0.239	0.602
Month 2	− 19.28 ± 9.05	−17.69 ± 9.41	− 20.88 ± 8.50	−18.76 ± 8.74	− 21.77 ± 8.49	0.459	0.248
Change (2–0)	0.81 ± 3.86	1.57 ± 4.38	0.04 ± 3.15	0.22 ± 2.48	− 0.01 ± 3.35	0.287	0.244
Month 6	−19.52 ± 9.09	−19.21 ± 9.89	−20.27 ± 7.24	−16.75 ± 15.91	−20.37 ± 5.71	0.096	0.798
Change (6–0)	1.30 ± 4.15	2.28 ± 4.80	0.27 ± 3.15	1.37 ± 5.98	0.07 ± 4.15	0.443	0.290
RNFLT
Baseline	170.99 ± 76.65	175.61 ± 71.51	166.63 ± 82.01	155.42 ± 69.87	169.68 ± 85.65	0.140	0.801
Month 2	77.76 ± 29.40	81.44 ± 25.66	73.23 ± 33.48	82.00 ± 59.11	71.27 ± 27.31	0.835	0.511
Month 6	65.35 ± 20.24	65.63 ± 19.43	65.10 ± 21.42	57.67 ± 16.20	66.34 ± 22.30	0.600	0.796

EECP enhanced external counterpulsation, BCVA best-corrected visual acuity in LogMAR, MD mean deviation, RNFLT retinal nerve fiber layer thickness
^aIndependent t-test comparing visual function between the EECP and control groups
^bOne way ANOVA comparing the control group, EECP group with EECP initiated within 2 weeks and EECP group with EECP initiated after 2 weeks

ISSN: 1471-2415